Les Laboratoires Servier has been granted a patent for anti-PD-1 antibodies, which are designed to treat diseases associated with PD-1 activity, such as cancer. The patent includes isolated nucleic acid molecules encoding specific heavy and light chain sequences of these antibodies. GlobalData’s report on Les Laboratoires Servier gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Les Laboratoires Servier, Cancer treatment biomarkers was a key innovation area identified from patents. Les Laboratoires Servier's grant share as of June 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.
Anti-pd-1 antibodies for cancer treatment
The granted patent US12030942B2 encompasses a series of claims related to isolated nucleic acid molecules that encode the heavy and light chain sequences of anti-PD-1 antibodies. These claims detail specific nucleotide sequences that correspond to various amino acid sequences, identified by SEQ ID numbers, which are integral to the antibody's structure. The patent also includes claims for vectors containing these nucleic acid molecules, host cells that incorporate them, and methods for producing the anti-PD-1 antibodies or their antigen-binding portions. Notably, the claims specify that the antibodies may exhibit certain properties, such as binding affinity to human PD-1 and the ability to inhibit tumor growth.
Additionally, the patent outlines variations of the anti-PD-1 antibodies, including those of specific isotypes, such as IgG1 and IgG4, with particular mutations at defined amino acid positions. The claims further emphasize the antibodies' functional characteristics, including their capacity to enhance cytokine secretion and block interactions between PD-1 and its ligands. Overall, the patent provides a comprehensive framework for the development and production of anti-PD-1 antibodies, which are significant in therapeutic applications, particularly in cancer immunotherapy.
To know more about GlobalData’s detailed insights on Les Laboratoires Servier, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
